Drogas emergentes: MDPV, Metilona y MDAI.
作者： José Francisco Navarro , Juan Manuel Antúnez
DOI:
关键词:
摘要: In this work we present a review of three emerging drugs: 3,4-methylenedioxypyrovalerone (MDPV), synthetic cathinone sold as bath salts, methylone, another with hallucinogenic effects, and 5,6-methylenedioxy-2-aminoindane (MDAI), MDMA analogue. For all the drugs, describe their pharmacological characteristics, toxicology, adverse effects well legal status.
researchgate.net 参考文章(37)
Richard B Rothman, Michael H Baumann, Serotonin releasing agents: Neurochemical, therapeutic and adverse effects Pharmacology, Biochemistry and Behavior. ,vol. 71, pp. 825- 836 ,(2002) , 10.1016/S0091-3057(01)00669-4
I M Murray-Lyon, A A Gunaid, N A G M Hassan, Khat (Catha edulis): health aspects of khat chewing. Eastern Mediterranean Health Journal. ,vol. 13, pp. 706- 718 ,(2007)
R Oberlender, D E Nichols, (+)-N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine as a discriminative stimulus in studies of 3,4-methylenedioxy-methamphetamine-like behavioral activity. Journal of Pharmacology and Experimental Therapeutics. ,vol. 255, pp. 1098- 1106 ,(1990)
Cathal T. Gallagher, Sulaf Assi, Jacqueline L. Stair, Suzanne Fergus, Ornella Corazza, John M. Corkery, Fabrizio Schifano, 5,6-Methylenedioxy-2-aminoindane: from laboratory curiosity to 'legal high'. Human Psychopharmacology-clinical and Experimental. ,vol. 27, pp. 106- 112 ,(2012) , 10.1002/HUP.1255
Joseph L. Antonowicz, Amy K. Metzger, Sai L. Ramanujam, Paranoid psychosis induced by consumption of methylenedioxypyrovalerone: two cases General Hospital Psychiatry. ,vol. 33, pp. 640- ,(2011) , 10.1016/J.GENHOSPPSYCH.2011.04.010
Michael Collins, Some new psychoactive substances: precursor chemicals and synthesis-driven end-products. Drug Testing and Analysis. ,vol. 3, pp. 404- 416 ,(2011) , 10.1002/DTA.315
Ilkka Antero Ojanperä, Pertti Kalevi Heikman, Ilpo Juhani Rasanen, Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Therapeutic Drug Monitoring. ,vol. 33, pp. 257- 263 ,(2011) , 10.1097/FTD.0B013E318208B693
Michael P. Johnson, Paul F. Conarty, David E. Nichols, [3H]Monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetaimne and p-chloroamphetamine analogues European Journal of Pharmacology. ,vol. 200, pp. 9- 16 ,(1991) , 10.1016/0014-2999(91)90659-E
Nicholas V Cozzi, Michael K Sievert, Alexander T Shulgin, Peyton Jacob, Arnold E Ruoho, Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines European Journal of Pharmacology. ,vol. 381, pp. 63- 69 ,(1999) , 10.1016/S0014-2999(99)00538-5
Robert T. Matthews, Thomas H. Champney, Gerald D. Frye, Effects of (+-)3,4-methylenedioxymethamphetamine (MDMA) on brain dopaminergic activity in rats. Pharmacology, Biochemistry and Behavior. ,vol. 33, pp. 741- 747 ,(1989) , 10.1016/0091-3057(89)90464-4